NCT02353299
Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers
See it on ClinicalTrials.gov ↗52 people
100%
0 womenmiddle line = equal numbers52 men
- Phase
- PHASE4
- Paid for by
- Currax Pharmaceuticals
- Finished
- 2016-03
- Health conditions
- Healthy
- Who could join
- Men only
- Ages
- 21 Years – 50 Years
- Average age
- Not reported
- Age 65+
- 0%
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 57.7% · Not reported 26.9% · Asian 9.6% · Black / African American 5.8% · American Indian / Alaska Native 0% · Native Hawaiian / Pacific Islander 0% · More than one race 0%
Women left out
- Men only
No women were allowed to join.
“Eligibility: Male participants only.”
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 50 Years.”
- Weight limit (BMI)
Women with a higher (or lower) body weight were turned away.
“Have a body mass index (BMI) \>35 kg/m2”
- No seizures
Women with epilepsy or past seizures were turned away.
“Have a history of epilepsy or serious head injury;”
- No smokers
Women who smoke or use nicotine were turned away.
“Self-reports use of products containing nicotine of greater than 15 cigarettes daily, or cannot avoid products containing nicotine during the normal sleep periods;”
Study titles and rules are shown in their original English.